Associated tags: Drug discovery, Disease, Biology, Medicine, MAT, GATC, Health, Artificial intelligence, Pharmaceutical industry, Science, Therapy, Research
Locations: CALIFORNIA
Retrieved on:
Wednesday, January 10, 2024
IRVINE, Calif., Jan. 10, 2024 /PRNewswire/ -- GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), was recognized as the Most Innovative Multiomic Technology Solutions Provider at the 2023 Global Excellence Awards.
Key Points:
- IRVINE, Calif., Jan. 10, 2024 /PRNewswire/ -- GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), was recognized as the Most Innovative Multiomic Technology Solutions Provider at the 2023 Global Excellence Awards.
- This award is a testament to GATC Health's groundbreaking work in the field of multiomic technology.
- The Global Excellence Awards, presented annually by Global Health & Pharma Magazine, recognize the achievements of companies and individuals in various industries worldwide.
- GATC Health's recognition in this prestigious international award program is a testament to its groundbreaking work in the field of multiomic technology.
IRVINE, Calif., July 12, 2023 /PRNewswire/ -- GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), recently announced a forward (2-for-1) stock split and new valuation of $500 million, doubling the company's previous $250 million valuation. Supporting the move to increase both shares and estimated valuation are a number of significant achievements, highlighted by a 9-drug candidate pipeline created in less than 18 months.
Key Points:
- IRVINE, Calif., July 12, 2023 /PRNewswire/ -- GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), recently announced a forward (2-for-1) stock split and new valuation of $500 million, doubling the company's previous $250 million valuation.
- The company is currently offering shares of common stock to accredited individuals and institutions at $5 per share of common stock at a valuation of $500 million.
- This Reg D, 506c offering follows a forward split of the company's common stock, bringing common shares outstanding to 89 million and fully diluted total to 135.67 million.
- The announced stock split doubles the number of shares of common stock, including the common stock underlying all warrants and options.
GATC,
IBM,
Partnership,
University,
Therapy,
Drug development,
Genetic engineering,
Post-traumatic stress disorder,
West Virginia University Health System,
University of California, Irvine School of Medicine,
University Health System,
IBM Watson,
Grubhub,
Health,
National Science Advisory Board for Biosecurity,
Research,
Attention,
Genentech,
Science,
Appalachian Mountains,
Silicon,
MAT,
UC,
Patient,
Single-nucleotide polymorphism,
Economic development,
Science Advisory Board,
Drug discovery,
R,
WVU,
Death,
Fentanyl,
News,
GoDaddy,
PTSD,
Disease,
Pharmaceutical industry,
Medical device,
West Virginia University,
Mylan,
Medicine IRVINE, Calif., April 5, 2023 /PRNewswire/ -- GATC Health Corp, a technology company transforming drug discovery and disease prediction using proprietary, disruptive artificial intelligence (AI), today announced that, as one of the first tenants in the new West Virginia University Innovation Corporation (WVUIC), it is establishing an AI-based life sciences/biotech research and development hub to create safer and more effective therapeutics and accelerate personalized medicine. GATC will expand the discovery of its own innovative drugs and diagnostics within the facility, partner with pharma companies to accelerate their drug development and support the distribution of GATC's 500+ personalized predictive health reports through health plan partners.
Key Points:
- GATC will also continue the development of its innovative drug candidate to treat fentanyl addiction—one of the leading causes of death in the U.S.
- I look forward to continuing my partnership with GATC Health as the center is established and their critical work begins at the WVU Innovation Corporation."
- WVU and the West Virginia University Health System, commonly branded as WVU Medicine , officially took ownership of the 1.2 million square foot property on Chestnut Ridge Road in March 2022 .
- For more information about the WVU Innovation Corporation, visit Innovation.WVU.edu .
Bacteria,
Albany Medical Center Prize,
Biotechnology,
National Medal,
Insulin,
Protein,
National Medal of Technology and Innovation,
University,
Roche,
Genentech,
Howard Hughes Medical Institute,
Science,
Drug discovery,
Health,
Therapy,
Medical research,
GATC,
National Medal of Science,
Artificial intelligence,
Pharmaceutical industry,
Medicine IRVINE, Calif., March 2, 2023 /PRNewswire/ -- GATC Health Corp, a technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), announced that Herbert Boyer, internationally recognized biotechnology and genetic engineering innovator, has joined GATC Health's board of advisors. Mr. Boyer is credited with helping create the modern biotech industry when he co-founded Genentech in 1976 with Robert Swanson, a venture capitalist, when they each invested $500 to start the company. In 1980 Genentech was the first biotech company to go public and used the $45 million raised to build the company to over 15,000 employees today.
Key Points:
- In 1980 Genentech was the first biotech company to go public and used the $45 million raised to build the company to over 15,000 employees today.
- "I have the opportunity to see many new biotechnology companies and their technologies' capabilities," said Mr. Boyer.
- "I am very selective as to which companies I become associated with and am very excited about joining the team at GATC.
- "We are extremely honored to welcome Mr. Boyer to the advisory board at GATC," stated Ian Jenkins, the company's Chief Science Officer.
Retrieved on:
Thursday, February 23, 2023
GATC,
DNA,
Artificial intelligence,
Research fellow,
Research,
Drug development,
Cowen,
Acquisition,
Drug discovery,
KKR,
Growth,
Doctor of Philosophy,
Therapy,
Chemical engineering,
DRI Capital,
Cooper Union,
Columbia University,
Art,
Securities research,
Medical device,
Medtech,
Science IRVINE, Calif., Feb. 23, 2023 /PRNewswire/ -- GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), welcomes Lin Yu, Ph.D., to its Board of Directors. Dr. Yu brings a powerful combination of academic acumen and financial experience in medtech and life sciences with BTIG Healthcare, KKR, Cowen & Co. and, most recently as Managing Director at Oppenheimer Healthcare Investment Banking to GATC's board.
Key Points:
- IRVINE, Calif., Feb. 23, 2023 /PRNewswire/ -- GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), welcomes Lin Yu, Ph.D., to its Board of Directors.
- Dr. Yu brings investment banking, gene sequencing technology and drug development expertise to GATC.
- "Dr. Yu has a very specific mandate as director with GATC," noted the company's president, Jeff Moses.
- We are extremely pleased to welcome him to our team and look forward to his contributions as a director on our board."
Retrieved on:
Wednesday, February 8, 2023
Science,
Union,
MAT,
Health,
Veteran,
Democrat,
OUD,
Post-traumatic stress disorder,
De novo,
Legislation,
PTSD,
Traffic barrier,
Speech,
GATC,
Dopamine,
NK,
Patient,
BBB,
Georgetown University,
Depression,
Artificial intelligence,
News,
Clinical trial,
Agitation,
White House,
Glioblastoma,
Behavior,
Gene,
FDA,
Genomics,
Drug discovery,
Opioid,
Cancer,
Mental health,
Pharmaceutical industry,
Nursing IRVINE, Calif., Feb. 8, 2023 /PRNewswire/ -- GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today responded to the release of President Biden's "Unity Agenda" as detailed in his first State of the Union address. The Unity Agenda's goals include ending cancer as we know it; delivering on the sacred obligation to veterans; tackling the mental health crisis; and beating the opioid and overdose epidemic. Not only are these four subjects the focus of the administration, they are each also current initiatives at GATC Health.
Key Points:
- Not only are these four subjects the focus of the administration, they are each also current initiatives at GATC Health.
- "President Biden's call for bipartisan endorsement of critical health issues outlined in his State of the Union address echo GATC Health's project pipeline," noted Dr. Robert Sorrentino, the company's Chief Medical Officer.
- Our uniquely powerful AI platform is fast-tracking solutions across all four fields, which is something every American can support."
- The first drug synthesized by GATC Health and put through pre-clinical studies specifically addresses the opioid addiction and overdose epidemic.
Retrieved on:
Wednesday, January 25, 2023
Safety,
Artificial intelligence,
Legislation,
AlphaGo,
DeepMind,
Human,
Congress,
Biomedical engineering,
Biomedicine,
GATC,
IBM Watson,
FDA,
Health,
MAT,
Drug discovery,
Animal,
Federal Food, Drug, and Cosmetic Act,
Risk,
Disease,
Biology,
Research,
Science,
Pharmaceutical industry,
Medical device IRVINE, Calif., Jan. 25, 2023 /PRNewswire/ -- GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that the FDA Modernization Act 2.0 signed into law in December 2022, ends an FDA mandate that experimental drugs must be tested on animals before they are used on humans in clinical trials. The new legislation allows emerging technologies, including GATC's computer modeling that predicts a potential drugs safety and efficacy in humans, to be used to advance drug leads to human trials without the requirement of animal testing.
Key Points:
- FDA Modernization Act 2.0 is expected to create more demand for GATC's drug discovery and development platform.
- In 1938, Congress passed the U.S. Federal Food, Drug, and Cosmetic Act, mandating animal toxicity testing.
- Since then, science and data has shown that animal testing is highly inconsistent in predicting toxic responses in humans.
- GATC's computer simulation models use human biological components to more accurately predict medical and biological outcomes than animal testing.
Retrieved on:
Wednesday, January 25, 2023
ETSU,
Artificial intelligence,
Municipality,
Bureau of Justice Assistance,
Emergency department,
Georgetown University,
Corrections,
Policy,
Georgetown University School of Medicine,
United States Department of Justice,
GATC,
Addiction,
Office of National Drug Control Policy,
Volunteering,
Volunteers of America,
ONDCP,
Private law,
Hospital,
Opioid,
East Tennessee State University,
Health,
MAT,
Drug discovery,
Research,
Science,
Legal Services Corporation,
Pharmaceutical industry IRVINE, Calif., Jan. 24, 2023 /PRNewswire/ -- GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that Tyrone Lam, COO of GATC Health, will present the company's fentanyl abatement drug candidates that were identified by GATC's AI-based drug discovery and development platform. The novel created by GATC are currently in preclinical drug evaluation studies. Guidelines allocated a portion of the Opioid Abatement Settlement funds for research and development, which includes GATC's opioid addiction abatement projects.
Key Points:
- The novel created by GATC are currently in preclinical drug evaluation studies.
- Guidelines allocated a portion of the Opioid Abatement Settlement funds for research and development, which includes GATC's opioid addiction abatement projects.
- The Opioid Settlement Abatement Summit – Model Guidance for States, Counties, Municipalities and Tribes will take place on Thursday January 26th, 2023 at Georgetown University and virtually, and focus on providing model abatement guidance for states, counties, municipalities and tribes to effectively plan for, implement and track opioid settlement funds.
- Equally prominent will be highlighting the successes and challenges of ongoing opioid litigations and the policies that have evolved to help reduce the harms associated with drug addiction.
Retrieved on:
Tuesday, November 29, 2022
IRVINE, Calif., Nov. 29, 2022 /PRNewswire/ -- GATC Health ("GATC" or "the Company"), a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that Tomas J. Philipson has joined its Medical Advisory Board. Dr. Philipson was a member of the White House Council of Economic Advisers from 2017 to 2019 and it's chairman from 2019 to 2020, leading a group of economists who advise the President on a wide range of policy issues. Dr. Philipson previously served in the public sector as the senior economic advisor to the FDA Commissioner of the Food and Drug Administration (FDA), as well as to the Administrator of the Centers for Medicare and Medicaid Services (CMS) during the second Bush Administration. Dr. Philipson is currently Co-Director of the Center for Choice in the Department of Economics at the University of Chicago. With decades of economic, healthcare and government leadership, Dr. Philipson will be a valued liaison for the Company to major pharmaceutical, healthcare and regulatory entities.
Key Points:
- Dr. Philipson is currently Co-Director of the Center for Choice in the Department of Economics at the University of Chicago.
- With decades of economic, healthcare and government leadership, Dr. Philipson will be a valued liaison for the Company to major pharmaceutical, healthcare and regulatory entities.
- "GATC Health's AI platform has unrivalled potential to transform the economics of drug discovery," said Dr. Philipson.
- "We are delighted to welcome Dr. Philipson to GATC Health's Advisory Board," said Jeff Moses, President of GATC Health.
Department,
Risk,
Health,
Education,
Company,
Global Health,
Medicine,
Marshall University,
Cocaine,
Preventive healthcare,
Multimedia,
Science,
Clinical associates,
Joan C. Edwards School of Medicine,
View,
Government,
Artificial intelligence,
Research,
GATC,
Opioid,
Methamphetamine,
Brain,
PTSD,
Time,
Internal medicine,
Editorial board,
Post-traumatic stress disorder,
Technology,
Public health,
Joan,
Therapy,
Coronavirus Scientific Advisory Board (Turkey),
Private practice,
Addiction,
Human body,
Drug discovery,
Limbic system,
Pharmaceutical industry Dr. Gupta is a primary care physician with a federal government agency and has specific expertise in Internal Medicine, Preventive Medicine, Public Health, Global Health and Women/LGBT Health.
Key Points:
- Dr. Gupta is a primary care physician with a federal government agency and has specific expertise in Internal Medicine, Preventive Medicine, Public Health, Global Health and Women/LGBT Health.
- Additionally, she serves on the Editorial Board of Internal Medicine Alerts, a leading scientific publication supporting evidence-based decision-making for medical providers.
- "Dr. Gupta brings a broad range of expertise to GATC Health's Scientific Advisory Board," stated Dr Jonathan Lakey, Chief of the company's science advisory board.
- "My goal is to bring to GATC Health the unique perspective of a practicing physician with years of experience," explained Dr. Gupta.
